© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Co-Diagnostics, Inc. (CODX) stock surged +75.30%, trading at $4.19 on NASDAQ, up from the previous close of $2.39. The stock opened at $3.13, fluctuating between $2.94 and $4.37 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 20, 2026 | 2.02 | 2.68 | 1.85 | 2.39 | 14.08M |
| May 19, 2026 | 1.95 | 2.75 | 1.80 | 1.97 | 113.99M |
| May 18, 2026 | 1.38 | 1.62 | 1.32 | 1.37 | 1.07M |
| May 15, 2026 | 1.45 | 1.50 | 1.26 | 1.29 | 413.98K |
| May 14, 2026 | 1.62 | 1.67 | 1.48 | 1.63 | 269.4K |
| May 13, 2026 | 1.77 | 1.80 | 1.50 | 1.60 | 334.3K |
| May 12, 2026 | 1.90 | 1.95 | 1.66 | 1.72 | 304.82K |
| May 11, 2026 | 2.55 | 2.65 | 1.82 | 1.90 | 1.49M |
| May 08, 2026 | 2.16 | 2.77 | 1.90 | 2.53 | 10.15M |
| May 07, 2026 | 1.61 | 2.00 | 1.61 | 1.93 | 352.36K |
| May 06, 2026 | 1.59 | 1.64 | 1.54 | 1.64 | 57.48K |
| May 05, 2026 | 1.57 | 1.64 | 1.55 | 1.59 | 58K |
| May 04, 2026 | 1.53 | 1.63 | 1.52 | 1.57 | 100.45K |
| Apr 30, 2026 | 1.52 | 1.65 | 1.49 | 1.55 | 90.96K |
| Apr 29, 2026 | 1.60 | 1.61 | 1.51 | 1.53 | 90.72K |
| Apr 28, 2026 | 1.65 | 1.69 | 1.57 | 1.63 | 70.94K |
| Apr 27, 2026 | 1.71 | 1.73 | 1.64 | 1.65 | 56.6K |
| Apr 23, 2026 | 1.71 | 1.77 | 1.65 | 1.71 | 189.24K |
| Apr 22, 2026 | 1.69 | 1.75 | 1.63 | 1.69 | 97.82K |
| Apr 21, 2026 | 1.72 | 1.76 | 1.60 | 1.64 | 240.55K |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
| Employees | 132 |
| Beta | 1.32 |
| Sales or Revenue | $991.47K |
| 5Y Sales Change% | 71.611% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |